JPH11500119A - インターロイキン１２を用いる脈管形成の阻害 - Google Patents

インターロイキン１２を用いる脈管形成の阻害

Info

Publication number
JPH11500119A
JPH11500119A JP8524631A JP52463196A JPH11500119A JP H11500119 A JPH11500119 A JP H11500119A JP 8524631 A JP8524631 A JP 8524631A JP 52463196 A JP52463196 A JP 52463196A JP H11500119 A JPH11500119 A JP H11500119A
Authority
JP
Japan
Prior art keywords
angiogenesis
treatment
disease
mice
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP8524631A
Other languages
English (en)
Japanese (ja)
Inventor
フォークマン，モーゼス・ユダ
トゥルーイット，ゲーリー・アーサー
フースト，エミーレ・ユーヘネ
Original Assignee
エフ・ホフマン−ラ ロシュ アーゲー
ザ・チルドレンズ・メディカル・センター・コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン−ラ ロシュ アーゲー, ザ・チルドレンズ・メディカル・センター・コーポレーション filed Critical エフ・ホフマン−ラ ロシュ アーゲー
Publication of JPH11500119A publication Critical patent/JPH11500119A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP8524631A 1995-02-16 1996-02-07 インターロイキン１２を用いる脈管形成の阻害 Pending JPH11500119A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38938295A 1995-02-16 1995-02-16
US389,382 1995-02-16
PCT/EP1996/000507 WO1996025171A1 (en) 1995-02-16 1996-02-07 Inhibition of angiogenesis using interleukin-12

Publications (1)

Publication Number Publication Date
JPH11500119A true JPH11500119A (ja) 1999-01-06

Family

ID=23538033

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8524631A Pending JPH11500119A (ja) 1995-02-16 1996-02-07 インターロイキン１２を用いる脈管形成の阻害

Country Status (8)

Country Link
EP (1) EP0809511A1 (xx)
JP (1) JPH11500119A (xx)
AU (1) AU4788396A (xx)
BR (1) BR9607427A (xx)
CA (1) CA2212370A1 (xx)
FI (1) FI973356A0 (xx)
TR (1) TR199700801T1 (xx)
WO (1) WO1996025171A1 (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060373A1 (ja) * 2002-12-27 2004-07-22 Santen Pharmaceutical Co., Ltd. 滲出型加齢黄斑変性治療剤

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6086869A (en) * 1996-11-22 2000-07-11 Toray Industries, Inc. Use of interferon-β or γ to treat retinal edema
US5858991A (en) * 1997-01-29 1999-01-12 Vanderbilt University Facilitation of wound healing with CM101/GBS toxin
US6028060A (en) * 1997-01-29 2000-02-22 Vanderbilt University Treatment of chronic inflammatory diseases with CM101/GBS toxin
US6670337B1 (en) 1998-01-29 2003-12-30 Yeda Reaearch And Development Co., Ltd. Facilitation of wound healing with CM101/GBS toxin
US5981508A (en) 1997-01-29 1999-11-09 Vanderbilt University Facilitation of repair of neural injury with CM101/GBS toxin
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
ES2216286T3 (es) * 1997-05-27 2004-10-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Uso de un nitroxido o de un profarmaco del mismo en el tratamiento profilactico y terapeutico del cancer.
WO1999022760A1 (en) * 1997-11-03 1999-05-14 The Wistar Institute Of Anatomy And Biology Method and compositions for inhibiting angiogenesis and treating cancer
US6689783B2 (en) 2001-03-29 2004-02-10 Schering Corporation Aryl oxime-piperazines useful as CCR5 antagonists
CN100469769C (zh) 2003-03-24 2009-03-18 弗·哈夫曼-拉罗切有限公司 作为逆转录酶抑制剂的苄基-哒嗪酮
AU2006303368B2 (en) 2005-10-19 2011-05-26 F. Hoffmann-La Roche Ag Non-Nucleoside Reverse Transcriptase Inhibitors
WO2008019968A1 (en) 2006-08-16 2008-02-21 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
ES2550152T3 (es) 2006-12-13 2015-11-04 F. Hoffmann-La Roche Ag Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa
WO2018017571A1 (en) * 2016-07-18 2018-01-25 Neumedicines, Inc. Uses of il-12 as a replacement immunotherapeutic

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0576669A4 (en) * 1992-01-16 1996-05-08 Repligen Corp Novel methods and compositions for treatment of angiogenic diseases
JPH06157344A (ja) * 1992-02-07 1994-06-03 Childrens Medical Center Corp:The 血管新生阻害のための医薬製剤及び血管新生阻害方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060373A1 (ja) * 2002-12-27 2004-07-22 Santen Pharmaceutical Co., Ltd. 滲出型加齢黄斑変性治療剤

Also Published As

Publication number Publication date
TR199700801T1 (xx) 1998-03-21
EP0809511A1 (en) 1997-12-03
WO1996025171A1 (en) 1996-08-22
FI973356A (fi) 1997-08-15
AU4788396A (en) 1996-09-04
BR9607427A (pt) 1998-06-23
MX9706188A (es) 1997-11-29
FI973356A0 (fi) 1997-08-15
CA2212370A1 (en) 1996-08-22

Similar Documents

Publication Publication Date Title
JP4065373B2 (ja) サリドマイドを有効成分とする医薬品製剤
JPH11500119A (ja) インターロイキン１２を用いる脈管形成の阻害
AU2008338525B2 (en) Compositions and methods of promoting wound healing
Ezra Neovasculogenesis. Triggering factors and possible mechanisms
AU640954B2 (en) Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or H2-receptor agonists
EP0579830A1 (en) Therapeutic agent for corneal lesion
AU2014233266A1 (en) The use of SDF-1 to mitigate scar formation
RU2730998C2 (ru) Композиции форболовых эфиров и способы их применения для лечения или уменьшения продолжительности цитопении
PT99265B (pt) Processo para a preparacao de composicoes farmaceuticas contendo interferon humano e metodo de tratamento de doencas proliferativas celulares
KR20160130403A (ko) 수지상 세포를 함유하는 의약 및 그 제조 방법
ES2207858T3 (es) Composicion farmaceutica activa para reducir la produccion de proteina mcp-1".
TWI310312B (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of macular degeneration
KR20190039145A (ko) 대체 면역요법으로서의 il-12의 용도
Woodruff The cytolytic and regulatory role of natural killer cells in experimental neoplasia
JPH10502371A (ja) リンホトキシンを用いる癌処置法
WO1988002632A1 (en) Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
MXPA97006188A (en) Inhibition of angiogenesis using interleucin
JPH0747545B2 (ja) 創傷治癒及び修復の修復段階を促進し、かつ感染した創傷及び糖尿病哺乳類の創傷の治癒を促進するためのｉｌ−４の用途
EP1722811B1 (en) Use of hepatocyte growth factor for promoting induction of vascular differentiation
JPH02121923A (ja) ４―キノリンカルボン酸誘導体とインターロイキン―２の同時投与による哺乳動物のガン治療
CN1189102A (zh) 白细胞介素－12对血管生成的抑制作用
EP0444691A1 (en) Use of interleukin-1 to enhance the immune response of weakly immunogenic tumors
WO1989001778A1 (en) Agents for prophylaxis and treatment of thrombopenia
JPH0429936A (ja) 悪性脳腫瘍治療用医薬組成物
JPS6348225A (ja) 制癌剤